Scinai ends PC111 licensing deal, shifts R&D focus to NanoAb platform
SCNI•NanoAb and CDMO priorities
NanoAb priorities include two IL-17 programs; intradermal psoriasis candidate seeks about EUR 12 million in Poland grant funding.
The CDMO pipeline showed about USD 3.1 million in committed customer orders as of Aug. 16, 2026; 2026 revenue target remains about USD 5 million.
Capital and management capacity redirected
The move avoids new PC111 funding commitments, reallocating capital and management capacity toward its CDMO unit’s commercial execution.
PC111 option and license arrangements ended
Scinai Immunotherapeutics ended its PC111 option and license arrangements with PinCell, shifting R&D focus to its NanoAb platform.
Option conditions expired Aug. 31, 2026, triggering termination; no extension agreement was reached.
